MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke
January 7, 2026 | Intelligent Commercialization
The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what AI-powered audience intelligence means for life sciences organizations heading into 2026.
How AI and LLMs are shaping audience intelligence in life sciences
In the episode, they examine how life sciences companies are approaching AI and Large Language Models (LLMs), the challenges created by gaps in data sets, and why context and real behavior matter when predicting how healthcare professionals and patients engage.
Why real behavior and high-quality data are critical for predictive accuracy
The discussion focuses on several key themes, including:
- The limitations of narrow or closed data inputs and how they restrict prediction accuracy
- The importance of understanding real behavior beyond a single organization’s data
- Why high-quality, holistic data sets are essential to improving LLM performance
- The role of subject matter experts in providing context that general-purpose models currently lack
- How data quality directly influences the usefulness and reliability of AI tools
Together, Jamie and Iris highlight how more precise, behavior-informed audience intelligence can support better decision-making as AI becomes increasingly central to life sciences marketing and engagement.
Listen to the full MM+M Podcast episode: “Beyond the algorithm: What AI-powered audience intelligence really means in 2026.”
Intelligent Commercialization™ in action
This perspective is core to how Inizio delivers Intelligent Commercialization™ – our unified, expert-driven approach that connects proprietary data, technology, and AI to unlock measurable impact across the product lifecycle. Platforms such as Cognitev™ and Predictev™ (referenced in the discussion) translate over 35M hours of real-world behavior into actionable intelligence, enabling clients to anticipate shifts, optimize engagement, and make smarter decisions with confidence.
This content was provided by Inizio
Company Details
Latest Content from Inizio
What oncologists really want from booth strategy
Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30…
How smart spaces and real-time strategy transformed ASCO® 2025
Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs – it was also a showcase for how technology is redefining congress engagement. Supporting…
The science is shifting in oncology: Are you ready to evolve with it?
Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic…
Reimagine health with Inizio.
At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each…
Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development
Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and…
Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot
This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across…
Navigating the future of AI: Insights from EphMRA’s one day meeting in London
Authored by: Ellie Forde and Mark Braund, Directors
Research conducted for Johnson and Johnson published in scientific journal
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address…
Autoimmune conditions: Living With syndicated patient reports
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our…